ShanXi C&Y Pharmaceutical Group Co.,LTD. (SHE:300254)
China · Delayed Price · Currency is CNY 10.58
+0.17 (1.63%)
Sep 30, 2025, 3:04 PM CST
SHE:300254 Revenue
ShanXi C&Y Pharmaceutical Group Co.,LTD. had revenue of 191.26M CNY in the quarter ending June 30, 2025, a decrease of -9.62%. This brings the company's revenue in the last twelve months to 818.49M, down -1.96% year-over-year. In the year 2024, ShanXi C&Y Pharmaceutical Group Co.,LTD. had annual revenue of 846.61M with 5.92% growth.
Revenue (ttm)
818.49M
Revenue Growth
-1.96%
P/S Ratio
3.31
Revenue / Employee
684.36K
Employees
1,196
Market Cap
2.71B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 846.61M | 47.30M | 5.92% |
| Dec 31, 2023 | 799.31M | -29.69M | -3.58% |
| Jan 1, 2023 | 829.00M | -101.38M | -10.90% |
| Jan 1, 2022 | 930.37M | 82.30M | 9.70% |
| Dec 31, 2020 | 848.07M | -283.73M | -25.07% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Medicine | 30.15B |
| WuXi AppTec | 41.90B |
| Shenzhen Mindray Bio-Medical Electronics | 32.94B |
| Sichuan Biokin Pharmaceutical | 441.19M |
| Shanghai United Imaging Healthcare | 10.98B |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.52B |
| Aier Eye Hospital Group | 21.94B |
| Yunnan Baiyao Group Co.,Ltd | 40.84B |